Aurobindo Pharma Limited (BOM:524804)
1,795.30
-11.70 (-0.65%)
At close: Nov 20, 2026
Aurobindo Pharma Market Cap
Aurobindo Pharma has a market cap or net worth of 1.04 trillion as of November 20, 2026. Its market cap has increased by 44.21% in one year.
Market Cap
1.04T
Enterprise Value
1.02T
Revenue
369.13B
Global Rank
n/a
Country Rank
n/a
PE Ratio
26.01
ChartMarket Cap Chart
Since July 1, 2002, Aurobindo Pharma's market cap has increased from 9.60B to 1.04T, an increase of 10,678.67%. That is a compound annual growth rate of 21.14%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 1.04T | 50.65% |
| Dec 31, 2025 | 687.09B | -11.35% |
| Dec 31, 2024 | 775.08B | 22.03% |
| Dec 29, 2023 | 635.16B | 147.32% |
| Dec 30, 2022 | 256.82B | -40.31% |
| Dec 31, 2021 | 430.28B | -20.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Laurus Labs | 1.25T |
| Zydus Lifesciences | 1.20T |
| Cipla | 1.15T |
| Mankind Pharma | 1.09T |
| Aurobindo Pharma | 1.04T |
| Glenmark Pharmaceuticals | 736.17B |
| Alkem Laboratories | 615.16B |
| Gland Pharma | 543.57B |